The value of single-pathogen antibacterial agents

Affiliations

¹ 1] Division of General Internal Medicine, Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, Los Angeles, California 90502, USA. [2] David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California 90095, USA.

Review

Brad Spellberg et al. Nat Rev Drug Discov. 2013 Dec.

. 2013 Dec;12(12):963.

doi: 10.1038/nrd3957-c1. Epub 2013 Nov 15.

¹ 1] Division of General Internal Medicine, Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, Los Angeles, California 90502, USA. [2] David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California 90095, USA.

No abstract available

References

1. Lewis K. Platforms for antibiotic discovery. Nature Rev. Drug Discov. 2013;12:371–387. - PubMed
1. Infectious Diseases Society of America Combating antimicrobial resistance: policy recommendations to save lives. Clin. Infect. Dis. 2011;52:S397–S428. - PMC - PubMed
1. Spellberg B, Bartlett JG, Gilbert DN. The future of antibiotics and resistance. N. Engl. J. Med. 2013;368:299–302. - PMC - PubMed
1. European Medicines Agency Addendum to the note for guidance on evaluation of medicinal products indicated for treatment of bacterial infections (CPMP/EWP/558/95 REV 2) to address indication-specific clinical data. European Medicines Agency. 2012 [online], http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guidelin....
1. Infectious Diseases Society of America White paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens. Clin. Infect. Dis. 2012;55:1031–1046. - PMC - PubMed